Bioequivalence and Bioavailability Forum

Hi Hötzi,

what a strange story. Thanks for posting.

I think there is more to it than meets the eye.

1. Isn't it a funny term "Integrity of its authorship". Is that the same as integrity of the study or the data? To me it sounds like doubt over who wrote the paper (or didn't) etc.
   
2. How can a paper first be published and then, afterwards, someone requires access to raw data and ethics approval?
   And who is someone? The ordinary reader can't ask about such things after publication (or she/he can, but to the best of my knowledge the journal does not make a requirement for publication that the authors provide raw data or other insights to readers upon request).

Strange one.

Dear all,

another one,¹ this time 3½ years (‼) after the paper² was accepted.

The Editor-in-Chief has retracted this article. After publication, concerns were raised with respect to the data shown in Fig. 9. The authors were unable to provide the raw data for further review. The Editor-in-Chief, therefore, no longer has confidence in the results and conclusions presented.
      Authors Rehab Nabil Shamma, Nouran O. Eladawy and Nadia M. Morsi agreed to this retraction but disagreed with the wording of the retraction notice. Author Abdelfattah A. Abdel­khalek does not agree with this retraction.

‘Integrity of authorship’ again, this time spiced with plagiarism:

The Editor-in-Chief has retracted³ this article.⁴ After publication, concerns were raised about the integrity of its authorship. The authors were asked for raw data but were unable to supply credible materials. Additionally, the article contains an overlap with a previously published article by different authors.⁵

There are two more retraction notes in the same issue. What’s going on? Sloppy peer review or what?

---

1. Retraction Note: Risedronate-Loaded Macroporous Gel Foam Enriched With Nanohydroxyapatite: Preparation, Characterization, and Oste­­o­­genic Activity Evaluation Using Saos-2 Cells. AAPS Pharm Tech. 2022; 23: Article 227. https://link.springer.com/article/10.1208/s12249-022-02383-w.
   
2. Morsi NM, Shamma RN, Eladawy NO, Abdelkhalek AA. Risedronate-Loaded Macroporous Gel Foam Enriched with Nano­hydroxy­apatite: Preparation, Characterization, and Osteogenic Activity Evaluation Using Saos-2 Cells. AAPS PharmSciTech. 2019; 20: 104. doi:10.1208/s12249-019-1292-4.
   
3. Retraction Note to: Sustained Delivery of Timolol Using Nanostructured Lipid Carriers-Laden Soft Contact Lenses. AAPS Pharm Tech. 2022; 23: Article 222. https://link.springer.com/article/10.1208/s12249-022-02382-x.
   
4. Tian C, Zeng L, Tang L, Yu J, Ren M. Sustained Delivery of Timolol Using Nanostructured Lipid Carriers-Laden Soft Contact Lenses. AAPS PharmSciTech. 2021; 22: 212. doi:10.1208/s12249-022-02382-x.
   
5. Guo Q, Jia L, Qinggeletu, Zhang R, Yang X. In vitro and in vivo evaluation of ketotifen-gold nanoparticles laden contact lens for controlled drug delivery to manage conjunctivitis. J Drug Deliv Sci Technol. 2021; 64. doi:10.1016/j.jddst.2021.102538.

WTF?

Else H. Dozens of papers co-authored by Nobel laureate raise concerns. Nature. 3 November 2022; 611(7934): 19–20. doi:10.1038/d41586-022-03032-9. Open access.